JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.3
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 14, Issue 2 (2022)
Iran J War Public Health 2022, 14(2): 125-131 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2022/03/6 | Accepted: 2022/03/26 | Published: 2022/05/30
Received: 2022/03/6 | Accepted: 2022/03/26 | Published: 2022/05/30
How to cite this article
Ghafil N, Jawad Kadhim Z, Dananah F, Abdiljaleel Alkaabi Y, Hassoun Y. Comorbidity Affecting the Severity of COVID-19 Infection in Iraq. Iran J War Public Health 2022; 14 (2) :125-131
URL: http://ijwph.ir/article-1-1123-en.html
URL: http://ijwph.ir/article-1-1123-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Toxicology and Pharmacology, Faculty of Pharmacy, University of Kufa, Kufa, Iraq
2- Faculty of Medicine, University of Kufa, Kufa, Iraq
3- Presidency University of Kufa, Kufa, Iraq
2- Faculty of Medicine, University of Kufa, Kufa, Iraq
3- Presidency University of Kufa, Kufa, Iraq
Abstract (1126 Views)
Aims: COIVD-19 Patients suffering from other diseases such as diabetic mellitus, asthma and obstructive pulmonary disease have increased morbidity and mortality rates resulting in more hospitalization and intensive therapy unit admissions. The study aimed to characterise and investigate the clinical pattern and the severity of symptoms in COVID-19 patients and to study its relationship with the coexisted morbidities.
Instrument & Methods: The data was collected from COVID-19 patients (N=202) who attended the Al-Shefaa center in Al-Najaf city, Iraq, during the period from 6 September 2020 to 20 January 2021. Demographical features, comorbidities, chronic diseases, and more prevalent symptoms were studied. The data was collected anonymously and processed using IBM SPSS 25 software. The descriptive statistics were performed.
Findings: 121 patients (59.9%) had a body mass index (BMI) of less than 18, while 38 patients (18.8%) have BMI ranged 18.5 to 24.9. Furthermore, 16 patients (7.9%) have BMI between 30-34.9 and only 6 (3%) have a BMI of 35-39.9. Patients with hypertension 9 (4.5%), respiratory diseases 7 (3.5%), atherosclerosis 6 (3%), diabetic Mellitus 6 (3%). Patients with moderate Covid-19 symptoms account for 54% of the cases while only 2% of the patients developed severe manifestations. Hair fall happened in 105 patients (52%), the severity can range from mild (43.6%) to severe (2.5%), and fever 61 (30%). Eighty-five patients (42.1%) of admitted patients with an incubation period of 2 weeks while 6 (3%) for 4 weeks. The requirement for artificial oxygen therapy was seen in 19 (10%) of cases, whereas 183 patients (90%) recovered without artificial oxygen support. Obesity was observed in more than 10% of infected patients, whereas more than 40% of cases have coexisted chronic diseases such as hypertension, diabetes mellitus, respiratory tract disorders and other chronic diseases. The duration of the disease ranged from a few days (15.3%) to 2 weeks (41%) to 4 weeks (3%).
Conclusion: The study highlights the possible role of obesity and concurrent chronic diseases on the magnitude and duration of COVID-19 illness
Instrument & Methods: The data was collected from COVID-19 patients (N=202) who attended the Al-Shefaa center in Al-Najaf city, Iraq, during the period from 6 September 2020 to 20 January 2021. Demographical features, comorbidities, chronic diseases, and more prevalent symptoms were studied. The data was collected anonymously and processed using IBM SPSS 25 software. The descriptive statistics were performed.
Findings: 121 patients (59.9%) had a body mass index (BMI) of less than 18, while 38 patients (18.8%) have BMI ranged 18.5 to 24.9. Furthermore, 16 patients (7.9%) have BMI between 30-34.9 and only 6 (3%) have a BMI of 35-39.9. Patients with hypertension 9 (4.5%), respiratory diseases 7 (3.5%), atherosclerosis 6 (3%), diabetic Mellitus 6 (3%). Patients with moderate Covid-19 symptoms account for 54% of the cases while only 2% of the patients developed severe manifestations. Hair fall happened in 105 patients (52%), the severity can range from mild (43.6%) to severe (2.5%), and fever 61 (30%). Eighty-five patients (42.1%) of admitted patients with an incubation period of 2 weeks while 6 (3%) for 4 weeks. The requirement for artificial oxygen therapy was seen in 19 (10%) of cases, whereas 183 patients (90%) recovered without artificial oxygen support. Obesity was observed in more than 10% of infected patients, whereas more than 40% of cases have coexisted chronic diseases such as hypertension, diabetes mellitus, respiratory tract disorders and other chronic diseases. The duration of the disease ranged from a few days (15.3%) to 2 weeks (41%) to 4 weeks (3%).
Conclusion: The study highlights the possible role of obesity and concurrent chronic diseases on the magnitude and duration of COVID-19 illness
Keywords:
References
1. Al-Kraety IAA, Al-Muhanna SG, Al-Hakeem AH. Coronavirus-2019 (Covid 19): A review of history, epidemology, structure and life cycle. Medico-legal Update. 2020;20(4):2309. [Link] [DOI:10.37506/mlu.v20i4.1969]
2. Ben H, Hua G, Peng Z, Zheng-Li S. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-54. [Link] [DOI:10.1038/s41579-020-00459-7]
3. Biscardi A. Coronavirus impacts on respiratory system and its phases. Med Rep Case Stu. 2020;5(4). [Link]
4. Chatterjee SK, Saha S, Munoz MNM. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy. Front Mol Biosci. 2020;7:196. [Link] [DOI:10.3389/fmolb.2020.00196]
5. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181-192. [Link] [DOI:10.1038/s41579-018-0118-9]
6. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J. A familial cluster of pneumonia associated with the. 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:14-23. [Link] [DOI:10.1016/S0140-6736(20)30154-9]
7. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-292.e6. [Link] [DOI:10.1016/j.cell.2020.02.058]
8. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. [Link] [DOI:10.1016/j.cell.2020.02.052]
9. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3. [Link] [DOI:10.1126/science.abb2507]
10. Marian AJ. The discovery of the ACE2 gene. Circ Res. 2013;112(10):1307-9. [Link] [DOI:10.1161/CIRCRESAHA.113.301271]
11. Mascolo A, Urbanek K, De Angelis A, Sessa M, Scavone C, Berrino. Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?. Heart Fail Rev. 2020;25(2):367-80. [Link] [DOI:10.1007/s10741-019-09837-7]
12. Nicholls J, Peiris M. Good ACE, bad ACE do battle in lung injury, SARS. Nat Med. 2005;11(8):821-2. [Link] [DOI:10.1038/nm0805-821]
13. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-90. [Link] [DOI:10.1007/s00134-020-05985-9]
14. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. [Link] [DOI:10.1172/JCI137244]
15. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-3. [Link] [DOI:10.1038/s41586-020-2012-7]
16. Giuseppe L, Johnny W, Brandon MH. Hypertension in patients with coronavirus disease. 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020;130(4):304-9. [Link]
17. Cui S, Chen S, Li X. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-4. [Link] [DOI:10.1111/jth.14830]
18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [Link] [DOI:10.1016/S0140-6736(20)30183-5]
19. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93-116. [Link] [DOI:10.1016/bs.aivir.2019.08.002]
20. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. [Link] [DOI:10.2807/1560-7917.ES.2020.25.3.2000045]
21. He W, Chen L, Chen L. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637-45. [Link] [DOI:10.1038/s41375-020-0836-7]
22. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318(5):E736-41. [Link] [DOI:10.1152/ajpendo.00124.2020]
23. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38. [Link] [DOI:10.1016/j.kint.2020.03.005]
24. Ong SWX, Young BE, Leo YS, Lye DC. Association of higher body mass index with severe coronavirus disease 2019 (covid-19) in younger patients. Clin Infect Dis. 2020;71(16):2300-2. [Link] [DOI:10.1093/cid/ciaa548]
25. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430-6. [Link] [DOI:10.1038/s41586-020-2521-4]
26. Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020;395(10236):1544-5. [Link] [DOI:10.1016/S0140-6736(20)31024-2]
27. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med. 2020;173(10):773-81. [Link] [DOI:10.7326/M20-3742]
28. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020;8(4):e21. [Link] [DOI:10.1016/S2213-2600(20)30116-8]
29. Zeng Z, Yu H, Chen H, Qi W, Chen L, Chen G, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit Care. 2020;24(1):525. [Link] [DOI:10.1186/s13054-020-03255-0]
30. Tang NL, Chan PK, Wong CK, To KF, Wu AK, Sung YM, et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem. 2005;51(12):2333-40. [Link] [DOI:10.1373/clinchem.2005.054460]
31. Zhang J, Tecson KM, McCullough PA. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. Rev Cardiovasc Med. 2020;21(3):315-9. [Link] [DOI:10.31083/j.rcm.2020.03.126]
32. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069. [Link] [DOI:10.1001/jama.2020.1585]
33. Koskinen A, Tolvi M, Jauhiainen M, Kekäläinen E, Laulajainen-Hongisto A, Lamminmäki S. Complications of COVID-19 nasopharyngeal swab test. JAMA Otolaryngol Head Neck Surg. 2021;147(7):672-4. [Link] [DOI:10.1001/jamaoto.2021.0715]
34. Mao L, Jin H, Wang M. Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-90. [Link] [DOI:10.1001/jamaneurol.2020.1127]
35. Wilson C. Concern coronavirus may trigger post-viral fatigue syndromes. New Sci. 2020;246(3278):10-1. [Link] [DOI:10.1016/S0262-4079(20)30746-6]
36. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221(11):1762-9. [Link] [DOI:10.1093/infdis/jiaa150]
37. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18-22. [Link] [DOI:10.1016/j.bbi.2020.03.031]
38. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH, et al. Contact tracing assessment of COVID-19 transmission dynamics in taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020;180(9):1156-63. [Link] [DOI:10.1001/jamainternmed.2020.2020]
39. Wölfel R, Corman VM, Guggemos W. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809):465-9. [Link] [DOI:10.1038/s41586-020-2196-x]
40. Im MC, Cui C, Shin KR. Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(7):671-3. [Link] [DOI:10.1056/NEJMc2027040]
41. Greenhalgh T, Knight M, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026 [Link] [DOI:10.1136/bmj.m3026]